Wall Street is positive on Mersana Therapeutics Inc (MRSN). On average, analysts give Mersana Therapeutics Inc a Buy rating. The average price target is $5.285, which means analysts expect the stock to increase by 238.78% over the next twelve months. That average ranking earns Mersana Therapeutics Inc an Analyst Rating of 14, which is better than 14% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating MRSN a Buy today. Find out what this means to you and get the rest of the rankings on MRSN!